MannKind Corporation
MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company developing and commercializing treatments for diabetes, heart failure, chronic kidney disease and orphan lung diseases. Its cardiometabolic products include Afrezza, an inhaled mealtime insulin; Furoscix, a subcutaneous furosemide treatment delivered… From the company’s description.
Over the twelve months to Sep 30, 2026, MannKind Corporation reported revenue of $413.37M, up 31.7% from a year earlier, and a net loss of $74.82M. Its operating margin was −2.9%, and operations used $66.24M in cash. In fiscal 2025, it reported revenue of $348.97M, up 22.2% from fiscal 2024, and net income of $5.86M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What MannKind Corporation does
In the company’s own words
MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company developing and commercializing treatments for diabetes, heart failure, chronic kidney disease and orphan lung diseases. Its cardiometabolic products include Afrezza, an inhaled mealtime insulin; Furoscix, a subcutaneous furosemide treatment delivered by an on-body infusor; and V-Go, a wearable insulin delivery device. MannKind commercializes these products directly in the United States and works with regional partners outside the country. Its orphan lung disease business includes Tyvaso DPI, which United Therapeutics commercializes and for which MannKind receives royalties and manufacturing revenue. The company also develops inhaled drug candidates, including MNKD-201 for idiopathic pulmonary fibrosis, using its Technosphere drug delivery platform. MannKind manufactures Afrezza and Tyvaso DPI powders at its Connecticut facility and acquired Furoscix developer scPharmaceuticals in October 2025; it acquired V-Go in 2022. Its brands include Afrezza, Furoscix and V-Go.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- DANBURY, CT
- Fiscal year end
- December
- CIK
- 899460
- SIC
- 2834
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns MannKind Corporation — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · MannKind Corporation’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do MannKind Corporation and its peers compare on margins and cash generation over ten years?”
- “Where did five years of MannKind Corporation's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in MannKind Corporation's last four quarterly filings that the numbers alone won't show?”